Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the partnership, RevOpsis is well-positioned to advance the clinical development of RO-104, a first-in-class lead candidate for the treatment of neovascular age-related macular degeneration.
Lead Product(s): RO-104
Therapeutic Area: Ophthalmology Product Name: RO-104
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Kemwell Biopharma Private Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 17, 2024
Details:
Through the funding, RevOpsis is well positioned to advance clinical development of RO-104, first-in-class lead candidate for the treatment of treatment of neovascular age-related macular degeneration.
Lead Product(s): RO-104
Therapeutic Area: Ophthalmology Product Name: RO-104
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $16.5 million Upfront Cash: Undisclosed
Deal Type: Funding April 25, 2024